Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-07-19 15:59 |
First Patient in Phase 1/2 Triple Combination Cohort
Expansion of COM701 with …
|
English | 36.0 KB | ||
| 2021-07-15 15:59 |
Compugen Doses First Patient in Phase 1 Combination Study of
COM902 and COM701…
|
English | 100.4 KB | ||
| 2021-07-15 15:59 |
Compugen Doses First Patient in Phase 1 Combination Study of
COM902 and COM701…
|
English | 35.9 KB | ||
| 2021-07-14 15:59 |
to Release Second Quarter 2021 Results and conderence call on
Wednesday, July …
|
English | 82.1 KB | ||
| 2021-07-14 15:59 |
to Release Second Quarter 2021 Results and conderence call on
Wednesday, July …
|
English | 35.9 KB | ||
| 2021-06-30 15:59 |
Compugen Doses First Patient in COM701/Opdivo®
Phase 1b Cohort Expansion Study
|
English | 100.0 KB | ||
| 2021-06-30 15:59 |
Compugen Doses First Patient in COM701/Opdivo®
Phase 1b Cohort Expansion Study
|
English | 35.9 KB | ||
| 2021-06-29 15:59 |
Compugen Presents Research Supporting PVRIG as a Novel
and Differentiated Chec…
|
English | 116.7 KB | ||
| 2021-06-29 15:59 |
Compugen Presents Research Supporting PVRIG as a Novel
and Differentiated Chec…
|
English | 35.9 KB | ||
| 2021-06-08 15:59 |
Compugen Announces Updated Data from Phase 1 Study of
COM701, First- in-Class …
|
English | 201.8 KB | ||
| 2021-06-08 15:59 |
Compugen Announces Updated Data from Phase 1 Study of
COM701, First- in-Class …
|
English | 36.0 KB | ||
| 2021-06-01 15:59 |
Compugen Management to Discuss COM701 Data Presented at ASCO at Event
Hosted b…
|
English | 107.8 KB | ||
| 2021-06-01 15:59 |
Compugen Management to Discuss COM701 Data Presented at ASCO at Event
Hosted b…
|
English | 35.9 KB | ||
| 2021-05-13 15:59 |
6K: Compugen Reports First Quarter 2021 Results
|
English | 152.1 KB | ||
| 2021-05-13 15:59 |
6K: Compugen Reports First Quarter 2021 Results
|
English | 35.8 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
